It was on the front page of my newspaper. It is in the data services I subscribe to for the American Society of Health-System Pharmacists and the American Society of Clinical Oncology. It is the feature of a new survey from the Hematology Oncology Pharmacy Association and is the lead-in for the Pharmacists’ Newsletter. It is on the nightly news, and it was explored in depth in the last issue of the Journal of Hematology Oncology Pharmacy (JHOP).
Background: Ifosfamide is a frequently used nitrogen mustard chemotherapeutic alkylating agent that is available commercially in either an aqueous or powder formulation. Documented toxicities related to ifosfamide include a unique neurotoxicity that has been associated with hypoalbuminemia, previous or concurrent administration of other neurotoxic agents, and renal dysfunction. Although data regarding ifosfamide neurotoxicity are available in adult medical oncology literature, studies regarding pediatric neurotoxicity are limited.
Almost one third of Americans are currently considered obese.1 As the number of patients with cancer who are overweight is increasing, the conventions of chemotherapy dosing are constantly being questioned. Because of the concern for overdosing obese patients, clinicians are routinely tasked with questions such as—Should we use actual body weight, ideal body weight, or something in between? Should we cap doses? Overdosing patients is a concern for all clinicians, but underdosing may be just as problematic.
Background: Serum creatinine–based formulas are used to estimate glomerular filtration rate when calculating carboplatin dosage with the Calvert formula. In overweight and obese patients, body weight applied to serum creatinine–based formulas may overestimate glomerular filtration rate. Overestimation may result in divergent carboplatin dosages that correlate with dose-limiting thrombocytopenia, treatment delays, and dose reductions.
Results 1 - 5 of 5